Plant-based enveloped Ara h 2 bioparticles display exceptional hypo-allergenicity

C. Castenmiller; M. Stigler; M. E. Kirpas; S. Versteeg; J. H. Akkerdaas; G. Pena-Castellanos; B. R. Blokhuis; S. C. Dreskin; L. Auger; R. Desgagnés; C. Martel; L. Mirande; B. Morel; J. Roberge; V. Stordeur; G. Tropper; L. P. Vézina; V. Gomord; E. C. de Jong; F. Redegeld; W. G. Shreffler; L. Aglas; R. van Ree

doi:https://doi.org/10.1111/cea.14294

Plant-based enveloped Ara h 2 bioparticles display exceptional hypo-allergenicity

C. Castenmiller, M. Stigler, M. E. Kirpas, S. Versteeg, J. H. Akkerdaas, G. Pena-Castellanos, B. R. Blokhuis, S. C. Dreskin, L. Auger, R. Desgagnés, C. Martel, L. Mirande, B. Morel, J. Roberge, V. Stordeur, G. Tropper, L. P. Vézina, V. Gomord, E. C. de Jong, F. RedegeldW. G. Shreffler, L. Aglas, R. van Ree

Research output: Contribution to journal › Comment/Letter to the editor › Academic

3 Citations (Scopus)

Original language	English
Pages (from-to)	577-581
Number of pages	5
Journal	Clinical and experimental allergy
Volume	53
Issue number	5
Early online date	2023
DOIs	https://doi.org/10.1111/cea.14294
Publication status	Published - May 2023

Keywords

allergen immunotherapy
bioparticle
food allergy
hypoallergenicity
peanut allergy
plant-based particle

Access to Document

https://doi.org/10.1111/cea.14294

Cite this

Castenmiller, C., Stigler, M., Kirpas, M. E., Versteeg, S., Akkerdaas, J. H., Pena-Castellanos, G., Blokhuis, B. R., Dreskin, S. C., Auger, L., Desgagnés, R., Martel, C., Mirande, L., Morel, B., Roberge, J., Stordeur, V., Tropper, G., Vézina, L. P., Gomord, V., de Jong, E. C., ... van Ree, R. (2023). Plant-based enveloped Ara h 2 bioparticles display exceptional hypo-allergenicity. Clinical and experimental allergy, 53(5), 577-581. https://doi.org/10.1111/cea.14294

@article{9c763a85da2f44f9bb24d4e9abb4fe3e,

title = "Plant-based enveloped Ara h 2 bioparticles display exceptional hypo-allergenicity",

keywords = "allergen immunotherapy, bioparticle, food allergy, hypoallergenicity, peanut allergy, plant-based particle",

author = "C. Castenmiller and M. Stigler and Kirpas, {M. E.} and S. Versteeg and Akkerdaas, {J. H.} and G. Pena-Castellanos and Blokhuis, {B. R.} and Dreskin, {S. C.} and L. Auger and R. Desgagn{\'e}s and C. Martel and L. Mirande and B. Morel and J. Roberge and V. Stordeur and G. Tropper and V{\'e}zina, {L. P.} and V. Gomord and {de Jong}, {E. C.} and F. Redegeld and Shreffler, {W. G.} and L. Aglas and {van Ree}, R.",

note = "Funding Information: This reported studies were embedded in the Siallergen consortium, which was supported by Health Holland. The work of the authors has further been supported by Angany Inc. (Quebec, Canada), the Austrian Science Funds (FWF Project P32189), the University of Salzburg priority program “Allergy-Cancer-BioNano Research Centre”, and a grant from the National Institute of Allergy and Infectious Diseases of the National Institute of Health, Bethesda, MD, USA (RO1AI165866 (SCD)). Funding Information: This reported studies were embedded in the Siallergen consortium, which was supported by Health Holland. The work of the authors has further been supported by Angany Inc. (Quebec, Canada), the Austrian Science Funds (FWF Project P32189), the University of Salzburg priority program “Allergy‐Cancer‐BioNano Research Centre”, and a grant from the National Institute of Allergy and Infectious Diseases of the National Institute of Health, Bethesda, MD, USA (RO1AI165866 (SCD)). Funding Information: Charlotte Castenmiller, Lorenz Aglas, and Maria Stigler received contract research funding and study material from Angany Inc. Louis‐P V{\'e}zina is a cofounder board member, and CEO of Angany Inc. R{\'e}jean Desgagn{\'e}s, Caroline Martel, Lydia Auger, Joanie Roberge, Bertrand Morel, Virginie Stordeur, Lucie Mirande, Guy Tropper, and V{\'e}ronique Gomord are employees of Angany Inc. Ronald van Ree received contract research funding and research material form Angany Inc. and besides received consulting fees and/or speaker's fees from Angany Inc. HAL Allergy BV, Citeq BV, ThermoFisher Scientific, Reacta Healthcare Ltd., Mission MightyMe, and AB Enzymes, and has stock options from Angany.",

year = "2023",

month = may,

doi = "https://doi.org/10.1111/cea.14294",

language = "English",

volume = "53",

pages = "577--581",

journal = "Clinical and experimental allergy",

issn = "0954-7894",

publisher = "Wiley-Blackwell",

number = "5",

}

Castenmiller, C, Stigler, M, Kirpas, ME, Versteeg, S , Akkerdaas, JH, Pena-Castellanos, G, Blokhuis, BR, Dreskin, SC, Auger, L, Desgagnés, R, Martel, C, Mirande, L, Morel, B, Roberge, J, Stordeur, V, Tropper, G, Vézina, LP, Gomord, V, de Jong, EC, Redegeld, F, Shreffler, WG, Aglas, L & van Ree, R 2023, 'Plant-based enveloped Ara h 2 bioparticles display exceptional hypo-allergenicity', Clinical and experimental allergy, vol. 53, no. 5, pp. 577-581. https://doi.org/10.1111/cea.14294

TY - JOUR

T1 - Plant-based enveloped Ara h 2 bioparticles display exceptional hypo-allergenicity

AU - Castenmiller, C.

AU - Stigler, M.

AU - Kirpas, M. E.

AU - Versteeg, S.

AU - Akkerdaas, J. H.

AU - Pena-Castellanos, G.

AU - Blokhuis, B. R.

AU - Dreskin, S. C.

AU - Auger, L.

AU - Desgagnés, R.

AU - Martel, C.

AU - Mirande, L.

AU - Morel, B.

AU - Roberge, J.

AU - Stordeur, V.

AU - Tropper, G.

AU - Vézina, L. P.

AU - Gomord, V.

AU - de Jong, E. C.

AU - Redegeld, F.

AU - Shreffler, W. G.

AU - Aglas, L.

AU - van Ree, R.

N1 - Funding Information: This reported studies were embedded in the Siallergen consortium, which was supported by Health Holland. The work of the authors has further been supported by Angany Inc. (Quebec, Canada), the Austrian Science Funds (FWF Project P32189), the University of Salzburg priority program “Allergy-Cancer-BioNano Research Centre”, and a grant from the National Institute of Allergy and Infectious Diseases of the National Institute of Health, Bethesda, MD, USA (RO1AI165866 (SCD)). Funding Information: This reported studies were embedded in the Siallergen consortium, which was supported by Health Holland. The work of the authors has further been supported by Angany Inc. (Quebec, Canada), the Austrian Science Funds (FWF Project P32189), the University of Salzburg priority program “Allergy‐Cancer‐BioNano Research Centre”, and a grant from the National Institute of Allergy and Infectious Diseases of the National Institute of Health, Bethesda, MD, USA (RO1AI165866 (SCD)). Funding Information: Charlotte Castenmiller, Lorenz Aglas, and Maria Stigler received contract research funding and study material from Angany Inc. Louis‐P Vézina is a cofounder board member, and CEO of Angany Inc. Réjean Desgagnés, Caroline Martel, Lydia Auger, Joanie Roberge, Bertrand Morel, Virginie Stordeur, Lucie Mirande, Guy Tropper, and Véronique Gomord are employees of Angany Inc. Ronald van Ree received contract research funding and research material form Angany Inc. and besides received consulting fees and/or speaker's fees from Angany Inc. HAL Allergy BV, Citeq BV, ThermoFisher Scientific, Reacta Healthcare Ltd., Mission MightyMe, and AB Enzymes, and has stock options from Angany.

PY - 2023/5

Y1 - 2023/5

KW - allergen immunotherapy

KW - bioparticle

KW - food allergy

KW - hypoallergenicity

KW - peanut allergy

KW - plant-based particle

UR - http://www.scopus.com/inward/record.url?scp=85148022551&partnerID=8YFLogxK

U2 - https://doi.org/10.1111/cea.14294

DO - https://doi.org/10.1111/cea.14294

M3 - Comment/Letter to the editor

C2 - 36779573

SN - 0954-7894

VL - 53

SP - 577

EP - 581

JO - Clinical and experimental allergy

JF - Clinical and experimental allergy

IS - 5

ER -

Plant-based enveloped Ara h 2 bioparticles display exceptional hypo-allergenicity

Keywords

Access to Document

Other files and links

Cite this